Piramal Pharma Q4FY25 results: Net profit jumps 52% YoY to Rs 154 crore; revenue up 8% to Rs 2,754 crore
Piramal Pharma Limited (PPL) reported a robust financial performance for the fiscal year ended March 31, 2025, with net profit rising over 411% to ₹91 crore, as compared to ₹18 crore in FY24. The growth was driven by strong momentum in its Contract Development and Manufacturing Organization (CDMO) business and operational efficiency across verticals.
The company's revenue from operations stood at ₹9,151 crore, marking a 12% year-on-year growth, while EBITDA increased by 15% to ₹1,580 crore. EBITDA margin remained steady at 17%. For the fourth quarter (Q4FY25), revenue rose 8% YoY to ₹2,754 crore, with net profit at ₹154 crore, up from ₹101 crore in the same period last year. CDMO leads the performance; quality track record maintained
The CDMO segment, which includes commercial manufacturing of on-patent molecules, clocked a 15% annual revenue growth to ₹5,447 crore. The business benefited from increased innovation-related work, which rose to 54% of CDMO revenues, and over 50% YoY growth in commercial revenues.
The company cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations, reinforcing its zero OAI (Official Action Indicated) status maintained since 2011. Strong showing in generics and consumer healthcare
The Complex Hospital Generics (CHG) business, with revenue of ₹2,633 crore, saw a notable boost from inhalation anesthetics and Baclofen. The company retained its #1 position in the US market for Sevoflurane, with a 44% share.
The India Consumer Healthcare (ICH) segment crossed a strategic revenue milestone of ₹1,000 crore, with power brands contributing 49% of total ICH revenue. The company launched 21 new products and 31 new SKUs during the year, and e-commerce sales surged 39% YoY. Balance sheet healthy; net debt under control
PPL maintained a Net Debt to EBITDA ratio of 2.7x, well below its previous 5.6x level. Net debt declined to ₹4,199 crore, from ₹3,932 crore in FY24. The company also reported a total equity of ₹8,125 crore. Looking ahead: Innovation and scale
Chairperson Nandini Piramal said FY25 was 'a steady year for the company,' highlighting performance across all business segments and reiterating the company's ambition to become a $2 billion revenue company with 25% EBITDA margins and high return on capital employed (ROCE). 'We crossed $1 billion in revenues with 12% YoY growth and 5x increase in net profits. Our focus on innovation, operational excellence, and expansion in the US and emerging markets has placed us on a strong trajectory for sustainable growth,' she added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 days ago
- New York Post
Feds investigate Gov. Kathy Hochul's home care program reforms after chaotic rollout: source
ALBANY – Federal investigators are probing Gov. Kathy Hochul's troubled consolidation of a popular $9 billion Medicaid homecare program, The Post has learned. The US Department of Justice has interviewed officials from Public Partnerships, LLC, the firm hand-picked by the state Department of Health to handle 'middleman' payroll services for the consumer directed personal assistance program, or CDPAP. 'They have been very active over the last couple months in investigating the transition and the various concerns that have been raised related to it,' a source who has had direct contact with investigators said. Advertisement The Department of Justice is probing Gov. Kathy Hochul's Medicaid homecare program reforms. Stephen Yang 'They are devoting significant resources to the investigation with an eye towards potential criminal or civil actions at the conclusion of the investigation,' the source added, noting that the investigators on the case are career professionals from the agency's consumer protection division. Hochul's administration forced the nearly 280,000 people receiving care under CDPAP to re-register from their current payroll services firm or 'fiscal intermediary' to PPL. The change was ostensibly made to cut down on the waste, fraud and abuse stemming from under-regulation of the hundreds of firms that used to handle the payroll services for CDPAP home caregivers. Advertisement A court stepped in at the last minute to try to alleviate an increasingly unrealistic April 1 deadline set by the DOH for the transition — with PPL massively backlogged and many home care aides in danger of going unpaid. Even with the injunction in place, caregivers are still reporting significant issues getting paid, even prompting legal action. Earlier this year, the DOJ's Consumer Affairs Branch chimed in on a federal lawsuit saying it would keep an eye on the situation. The Hochul administration forced people receiving care under the CDPAP to re-register their current payroll services firm or 'fiscal intermediary' to Public Partnerships, LLC. zinkevych – The six-page 'statement of interest' expressed concerns that the health department proceeded with the transition despite significant warning signs it would fail, made false statements about impacts on consumers' eligibility for the Medicaid program, and did not ensure sensitive personal health data was protected during the process. Advertisement 'The transition process—transferring, within a short period of time, CDPAP services for hundreds of thousands of patients from hundreds of Fiscal Intermediaries to PPL—has been plagued by myriad structural, operational, and logistical defects,' Assistant Director of DOJ's Consumer Affairs Branch, Patrick Runkle, wrote in the court filing. The source said the DOJ's probe follows those same lines, and also could extend to allegations surrounding the impetus of Hochul's push to overhaul the program, including allegations the $1.05 billion contract PPL was awarded was rigged. 'They're interested in the full-scope of the transition, the selection and transition,' the source said. Advertisement The DOJ didn't respond to a request for comment. A Hochul spokesperson called the reforms 'much-needed' and said they would stop 'the runaway bureaucratic spending' that put the program 'on the verge of a fiscal crisis.' 'Removing more than 600 administrative middlemen is a commonsense approach to cutting waste, fraud and abuse,' the spokesperson said in a statement. 'The CDPAP transition is proceeding effectively and the Department of Health will continue working with all stakeholders to ensure that consumers and workers receive the care and support they need,' Hochul's spokesperson continued. A PPL spokesperson said the company would continue to 'work diligently to support' consumers and workers who wish to continue in the program. A health department spokesperson said the agency 'remains committed to prioritizing continuity of care for consumers and fair treatment of personal assistants,' but did not comment further.
Yahoo
5 days ago
- Yahoo
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025. Three (3) Months of 2025 Financial Summary Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company's CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on May 7, 2025, CDMO revenues for the full year 2024 were $658 thousand. The year-over-year increase in revenues for the first quarter of 2025 reflects a higher number of contracts executed during the period, driven by continued growth in the CDMO business. R&D expenses for the three months ended March 31, 2025, amounted to $1,296 thousand, compared to $1,568 thousand for the same period in 2024. The decrease was primarily due to lower wages and reduced direct R&D expenses. Marketing, general and administrative expenses for the three months ended March 31, 2025, amounted to $500 thousand compared to $484 thousand for the three months ended March 31, 2024. Financial income, net, for the three months ended March 31, 2025, amounted to $11 thousand, compared to financial expenses of $231 thousand for the same period in 2024. The improvement was primarily due to the conversion of the EIB loan into preferred shares of the Company stock in the third quarter of 2024. Net loss for the three months ended March 31, 2025, was $1,557 thousand, compared to a net loss of $2,159 thousand for the three months ended March 31, 2024. The decrease was primarily due to lower R&D expenses, reduced financial expenses, and the recognition of gross income. As of March 31, 2025, Scinai had cash and cash equivalents and short-term deposits of $1,018 thousand compared to $1,964 thousand as of March 31, 2024. About Scinai Immunotherapeutics Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects. Company website: Company Contacts Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@ Business Development | +972 8 930 2529 | bd@ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2025 and thereafter; failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other nanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of nanoAbs will not be met or that Scinai will not be successful in bringing the nanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for nanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 7, 2025, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason. Logo - View original content: SOURCE Scinai Immunotherapeutics Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
The 9th International Festival of the Intangible Cultural Heritage Kicks off
CHENGDU, China, May 29, 2025 (GLOBE NEWSWIRE) -- The 9 th International Festival of the Intangible Cultural Heritage is held from May 28 to June 3 at the Chengdu International Intangible Cultural Heritage Expo Park. Co-hosted by the Sichuan Provincial People's Government, the Ministry of Culture and Tourism, UNESCO, and the National Commission of the People's Republic of China for UNESCO, the festival features nearly 600 representative intangible cultural heritage (ICH) items for exhibitions and performances. Centered on integrating ICH into modern life, it showcases innovative achievements in the fusion of traditional culture and technology, while fostering in-depth collaborations between ICH-branded intellectual properties (IPs) and related industries. A "Guest Country + Guest City" mechanism is introduced for the first time, with Malaysia serving as the guest country and Algiers (Algeria), Penang (Malaysia), Chiang Mai (Thailand), and Bari (Italy) as guest cities. The event gathers 400 participants, including ICH inheritors, scholars, government officials, and foreign diplomatic envoys stationed in China, representing over 60 countries and regions. A dedicated "Technology Empowering ICH" section is arranged this time, where 16 research institutions and tech enterprises will present over 30 interactive devices. Drawing inspiration from ICH items such as silk weaving and the folklore of Journey to the West, the exhibits have incorporated VR tours, culture-themed games and short videos, to give fresh life to traditions. Since its inception in 2007, the International Festival of the Intangible Cultural Heritage has been successfully held for eight consecutive sessions, establishing itself as a vital platform for showcasing heritage preservation achievements and facilitating cultural exchange. As the host city of the event, Chengdu has demonstrated equally remarkable accomplishments in local intangible cultural heritage preservation. Chengdu is home to 336 ICH items recognized at the city level or higher, including 25 national-level treasures. The city also has 382 officially certified ICH practitioners, with 21 of them holding the prestigious national-level master title. Statistics reveal that Chengdu holds over 260 cultural heritage events for the public every year, attracting 300,000 participants. These activities have triggered widespread public enthusiasm for preserving intangible cultural heritage. Now Chengdu has 14 special cultural districts featuring ICH, along with 227 traditional craft product lines. Together, they bring an annual economic value of 30 billion yuan and provide jobs for more than 50,000 local residents. The "Chengdu Handicraft" public brand has cumulatively generated over 400 million yuan in sales for heritage inheritors, demonstrating the tremendous commercial potential of ICH industrialization. Source: The Sichuan Provincial People's Government CONTACT: Contact person: Ms. Hou, Tel: 86-10-63074558Sign in to access your portfolio
